Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Next Previous
X
Search
Trial Profile

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisaftoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Ascentage Pharma

    • Most Recent Events

    • 17 Nov 2024 According to Ascentage Pharma media release, company announced that a New Drug Application for lisaftoclax, for the treatment of patients with relapsed or refractory (r/r) CLL/SLL has been accepted and recommended the Priority Review designation by the Center for Drug Evaluation) of China National Medical Products Administration. This NDA is based on results from this pivotal registrational Phase II study in China (APG2575CC201).
    • 22 Jan 2024 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.
    • 22 Jan 2024 Planned primary completion date changed from 1 Oct 2023 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top